Ascelia Pharma AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was SEK 22.81 million compared to SEK 33.49 million a year ago. Basic loss per share from continuing operations was SEK 0.68 compared to SEK 1.02 a year ago.
For the six months, net loss was SEK 51.88 million compared to SEK 62.31 million a year ago. Basic loss per share from continuing operations was SEK 1.54 compared to SEK 2.03 a year ago.